Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
View Patent ↗A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d 50 in the range 0.1-2 μm and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d 50 in the range of more than 0.5 and up to 5 μm.
1. A process for preparing a powder comprising at least one human coagulation factor protein and a lactic acid polymer, the process comprising the steps of:
a) mixing and dispersing a lactic acid polymer with a particle size d 50 in the range 0.1-2 μm and at least one human coagulation factor protein in water to form a dispersion comprising the lactic acid polymer, the at least one human coagulation factor protein, and water,
b) drying the dispersion to obtain a dried mass,
c) compressing the dried mass from the dispersion to obtain a compressed dried mass, and
d) comminuting the compressed dried mass from the dispersion to obtain the powder comprising the at least one human coagulation factor protein and the lactic acid polymer, wherein the powder has a particle size d 50 in the range of more than 0.5 and up to 5 μm.
2. The process according to claim 1 , wherein
the lactic acid polymer is a copolymer polymerized from a lactide unit and a glycolide unit.
3. The process according to claim 1 , wherein
the at least one human coagulation factor protein is at least one member selected from the group consisting of factor I=fibrinogen, factor II=prothrombin, factor III=tissue factor, factor V=proaccelerin, factor VII=proconvertin, factor VIII=antihemophilic factor A, factor IX=antihemophilic factor B, factor X=Stuart Prower factor, factor XI=plasma thromboplastin antecedent, factor XII=Hageman factor, factor XIII=fibrin-stabilizing factor, von Willebrand factor, prekallikrein, antithrombin III, heparin cofactor II, Protein C, Protein S, protein Z, protein Z-related proteinase inhibitor, plasminogen, alpha-plasma 2-antoplasmin, tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, and plasminogen activator inhibitor-2, and any combination thereof.
4. The process according to claim 1 , wherein
the human coagulation factor protein is comprised in a human blood plasma preparation.
5. The process according to claim 4 , wherein
the human coagulation factor protein is factor VIII, factor IX, von Willebrand factor or any combination thereof.
6. The process according to claim 4 , wherein
the human blood plasma preparation comprises von Willebrand factor in a not-physiological concentration.
7. The process according to claim 4 , wherein
the human blood plasma preparation comprises 0.05 to 5% by weight of human factor VIII and 95 to 99.95% by weight of at least one other plasma protein or a further pharmaceutical excipient or both.
8. The process according to claim 4 , wherein
the human blood plasma preparation comprises 25 to 1000 IU/ml of human factor VIII protein activity at a concentration of 100 mg/ml water.
9. The process according to claim 4 , wherein,
in step a), the ratio between the human blood plasma preparation, which comprises the human coagulation factor protein, and the lactic acid polymer, is from 30:70 to 5:95 parts by weight.
10. The process according claim 1 , wherein
the human coagulation factor protein is a recombinant factor VIII.
11. The process according to claim 1 , wherein,
in step a), a 5 to 50 fold excess of water by weight is used to nix and disperse the human factor VIII containing human blood plasma preparation and the lactic acid polymer.
12. The process according to claim 1 , wherein,
in step b), the drying of the dispersion is performed by lyophilization or by spray drying.
13. The process according to claim 1 , wherein,
in step c), the compression of dried mass from the dispersion is performed at a compression force from 0.2 to 2 kN.
14. A powder, obtainable by a process according to claim 1 , wherein
the powder comprises a human coagulation factor protein and a lactic acid polymer, and
the powder has a particle size d 50 in the range of 0.5 to 5 μm.
15. A pharmaceutical composition, comprising:
the powder according to claim 14 in dry, dispersed, or dissolved form.
16. A method for producing a pharmaceutical composition, the method comprising:
adding the powder according to claim 14 to the pharmaceutical composition.
17. The method according to claim 16 , wherein
said pharmaceutical composition is suitable for the treatment of a disease or a genetic disorder associated with the human coagulation factor protein.